Prevention of Asthma Exacerbations Using Dupilumab in Urban Children and Adolescents
Status:
Not yet recruiting
Trial end date:
2025-03-31
Target enrollment:
Participant gender:
Summary
This is a multi-center, double-blind, placebo-controlled, randomized trial of dupilumab
adjunctive therapy for prevention of asthma exacerbations in urban children and adolescents
with T2-high exacerbation-prone asthma.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators:
Childhood Asthma in Urban Settings (CAUSE) Regeneron Pharmaceuticals Rho Federal Systems Division, Inc.